leisure time -WSS

leisure time

author：explore 2025-08-12 09:09:17 - browse：5188

Boxes of Ozempic photo illustration. -- health coverage from STAT — Mario Tama/Getty Images

LONDON — Novo Nordisk’s diabetes medication Ozempic cut the risk of patients developing advanced kidney disease or dying from kidney or heart complications, the company said Tuesday, adding to the evidence the wildly popular drug has broader health benefits for patients beyond addressing their diabetes.

Overall, Ozempic lowered the risk of progression of patients’ kidney disease and of related health events by 24% versus placebo, according to the topline results. The company, which will present full data from the study later this year, said it would file for an expanded approval of Ozempic based on the data in both the U.S. and Europe.

The positive announcement had been expected since October, when Novo announced it was ending the FLOW trial early because an interim data analysis showed the drug was surpassing the study’s goals. Still, the results provide an important data point for Novo both as its medicines face increasing competition and as it tries to get more insurers to cover its related obesity drug Wegovy.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Covid vaccine financial winners and losers, from Pfizer to Novavax

WSS

Study says nonprofit hospitals fall short in charity care spending

Can we make enough H5N1 bird flu vaccine if there's a pandemic?

Bird flu: Don't repeat Covid's 'health versus the economy' framing

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Readout LOUD podcast: Live from STAT Breakthrough Summit West

Data integrity in scientific journals requires "effort" by publishers, institutions

hotspot

leisure time

Wikipedia

DIEP, the 'gold standard' of breast reconstruction, is under threat

Readout LOUD podcast: mifepristone case, GLP

Hollywood unions extend contract negotiations for actors

Readout LOUD podcast: Live from STAT Breakthrough Summit West

Hepatitis C has a cure — but many Americans still lack access to it

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

Moonlake's readout produced a cash windfall. Risks remain

Readout LOUD podcast: Live from STAT Breakthrough Summit West

Continuity nursing helped my family in our darkest PICU moments

NVIDIA and Google execs on the future of AI and drug discovery

focus

FDA's naming rule on biosimilars has undermined competition

With measles on the rise, a personal story of a devastating disease

Roche subsidiary Foundation Medicine opens new headquarters

Venture capitalist Bob Kocher on the state of digital health

There's no autism epidemic. It's an autism diagnosis epidemic

Primary care physicians play key roles in Alzheimer's management

knowledge

focus

focus

focus